SCHEMBL4350316

SCHEMBL4350316

O=C(NCc1ccccc1)Nc1cc(F)cc(F)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
MAOB P27338 1/20 0.54
CFD P00746 1/20 0.54
KDM4E B2RXH2 6/20 0.52
GSK3B P49841 1/20 0.52
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
TRPV1 Q8NER1 1/20 0.51
ALDH1A1 P00352 5/20 0.50
LMNA P02545 3/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6225613 0.89 RAB9A (0.46) POLBRAB9ANPC1MAOBCFD
SCHEMBL4347712 0.86 RAB9A (0.60) POLBRAB9ANPC1CA12CA1
SCHEMBL4346450 0.86 POLB (0.52) POLBRAB9ANPC1MAOBCFD
SCHEMBL4347640 0.84 MTOR (0.57) POLBRAB9ANPC1MAOBTRPV1
SCHEMBL4347160 0.83 KDM4E (0.62) POLBRAB9ANPC1MAOBCFD
SCHEMBL4349136 0.82 RAB9A (0.51) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4349130 0.81 RAB9A (0.61) POLBRAB9ANPC1MAOBCFD
SCHEMBL4341436 0.80 SMN1; SMN2 (0.68) POLBRAB9ANPC1MAOBKDM4E
SCHEMBL4949618 0.76 LNPEP (0.55) POLBRAB9A
SCHEMBL4353956 0.75 KDM4E (0.58) POLBRAB9ANPC1KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 POLB 3571/4885RAB9A 4228/4885NPC1 815/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 POLB 2402/4885RAB9A 4588/4885NPC1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.